KLK4 and hereditary angioedema: Data from the ex vivo fluorogenic assay of kallikrein activity using samples from healthy volunteers and HAE patients who received lanadelumab were compared with kallikrein activity results from clinical studies of lanadelumab [18, 19] (Fig. 2).